Bupropion in the treatment of pathological gambling: A randomized, double-blind, placebo-controlled, flexible-dose study

Journal of Clinical Psychopharmacology

Volumn 27, Issue 2, 2007, Pages 143-150

  Black, Donald W ^a   Arndt, Stephan ^a,b   Coryell, William H ^a   Argo, Tami ^c   Forbush, Kelsie T ^d   Shaw, Martha C ^a   Perry, Paul ^b   Allen, Jeff ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d E11 SSH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; PLACEBO;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; MALE; NERVOUSNESS; OUTCOME ASSESSMENT; PATHOLOGICAL GAMBLING; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; STOMACH DISCOMFORT; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; BUPROPION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GAMBLING; HEADACHE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PATIENT DROPOUTS; TREATMENT OUTCOME; XEROSTOMIA;

EID: 34247176792     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000264985.25109.25     Document Type: Article

References (41)

1. National Opinion Research Center at the University of Chicago (NORC): Gambling Impact and Behavior Study. Report to the National Gambling Impact Study Commission, April 1, 1999.
2. Cunningham-Willams RM, Cottler LB. The epidemiology of pathological gambling. Semin Clin Neuropsychiatry. 2001;6:155-166.
3. Lester D. Access to gambling opportunities and compulsive gambling. Int J Addict. 1994;29:1611-1616.
4. Shaffer HJ, Korn DA. Gambling and related mental disorders: a public health analysis. Annu Rev Public Health. 2002;23:171-212.
5. Cunningham JA. Little use of treatment among problem gamblers. Psychiatr Serv. 2005;56:1024-1025.
6. Ladouceur R, Sylvain C, Letarte H, et al. Cognitive treatment of pathological gamblers. Behav Res Ther. 1998;36:1111-1119.
7. Petry NM. Psychosocial treatments for pathological gamblers. Psychiatr Ann. 2002;32:192-196.
8. Hollander E, Good E, Pallanti S, et al. Pharmacologic treatment of pathological gambling. J Gambling Stud. 2005;21:101-110.
9. Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49:914-921.
10. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163:303-312.
11. Kim SW, Grant JE, Adson DE, et al. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002;63:501-507.
12. Grant JE, Potenza MN, Blanco C, et al. Paroxetine treatment of pathological gambling: a multi-center randomized controlled trial. Int Clin Psychopharmacol. 2003;18:243-249.
13. Saiz-Ruiz J, Blanco C, Ibanez A, et al. Sertraline treatment of pathological gambling. J Clin Psychiatry. 2005;66:28-33.
14. Blanco C, Petkova E, Ibanez A, et al. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14:9-15.
15. Hollander E, DeCaria C, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry. 2000;47:813-817.
16. Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry. 2002;63:44-48.
17. Pallanti S, Rossi NB, Sood E, et al. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. J Clin Psychiatry. 2002;63:1034-1039.
18. Grant JE, Potenza MN. Escitalopramtreatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol. 2006;21:203-209.
19. Hollander E, Pallanti S, Allen A, et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162:137-145.
20. Pallanti S, Quercioli L, Sood E, et al. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry. 2002;63:559-564.
21. Dannon PN, Lowengrub K, Gonopolski Y, et al. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol. 2005;28:6-10.
22. Specker SM, Carlson GA, Christenson GA, et al. Impulse control disorders and attention deficit disorder in pathological gamblers. Ann Clin Psychiatry. 1995;7:175-179.
23. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001;158:282-288.
24. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-released bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-691.
25. Black DW. An open-label trial of bupropion in the treatment of pathological gambling. J Clin Psychopharmacol. 2004;24:108-110.
26. Lesieur HR, Blume SB. The South Oaks Gambling Screen (SOGS): a new instrument for identification of pathological gamblers. Am J Psychiatry. 1987;144:1184-1188.
27. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
28. Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM-IV. New York, NY: New York State Psychiatric Institute, Biometrics Research; 1994.
29. Pfohl B, Zimmerman M, Blum N. Structured Interview for DSM-IV Personality (SIDP-IV). Washington, DC: American Psychiatric Publishing, Inc; 1997.
30. DeCaria CM, Hollander E, Begas T. Reliability and validity of a pathological gambling modification of the Yale-Brown Obsessive-Compulsive Scale: preliminary findings. Paper presented at: Third International Conference on OCD, Madeira, Portugal. September 1998.
31. Sobell LC. Alcohol Time Line Follow Back Users Manual. Toronto, Ontario, Canada: Addiction Research Foundation; 1995.
32. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of HEW Publication; 1976:217-222.
33. Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766-771.
34. Barkley RA. Attention-Deficit Hyperactivity Disorder: Handbook for Diagnosis and Treatment. New York, NY: Guilford Press; 1990.
35. Sheehan DV. The Anxiety Disease. New York, NY: Bantam Books; 1986.
36. SAS Institute, Inc. The SAS System for Windows (Version 8). Cary, NC: SAS Institute, Inc.; 1999.
37. Shaffer HJ, LaPlante DA, LaBrie RA, et al. Toward a syndrome model of addiction: multiple expressions, common etiology. Harv Rev Psychiatry. 2004;12:1-8.
38. Dannon PN, Lowengrub K, Muslin E, et al. Sustained-release bupropion in the treatment of SSRI non-responder pathological gamblers: pilot study and review of the literature. Therapy. 2005;2:753-757.
39. Dannon PN, Lowengrub K, Muslin E, et al. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. J Clin Psychopharmacol. 2005;25:593-596.
40. Stolk P, Ten Berg MJ, Hemels MEH, et al. Meta-analysis of placebo rates in major depressive disorder trials. Ann Pharmacother. 2003;37:1891-1899.
41. Friedenberg BM, Blanchard EB, Wulfert E, et al. Changes in physiological arousal to gambling cues among participants in motivationally enhanced cognitive-behavior therapy for pathological gambling: a preliminary study. Appl Psychophysiol Biofeedback. 2002;27:251-260.